• Skip to primary navigation
  • Skip to main content
SRI logo
  • About
    • Press room
    • Our history
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Search
Close
Bios September 8, 2021

Peter Madrid

Vice President, SRI Biosciences

Peter Madrid, Ph.D., is head of the Biosciences Division Applied Research group in Menlo Park. His team focuses on developing innovative technologies to accelerate the discovery of drugs and diagnostics for significant unmet medical needs. The group has produced a pipeline of drug candidates, primarily in the areas of cancer and infectious diseases.

Dr. Madrid has led multidisciplinary teams conducting research projects on infectious disease drug discovery, automated chemical synthesis, high-throughput screening methodologies and AI-driven drug discovery. He has published numerous papers in the field of anti-infectives drug discovery and is an inventor on several patents on drug discovery technologies.

He received his Ph.D. in chemistry and chemical biology from the University of California, San Francisco, and his B.S. in chemistry from the University of California, Santa Cruz.

View Dr. Madrid’s publications on PubMed and Google Scholar.

Recent publications

more +
  • Accelerating space radiation countermeasure development through drug repurposing 

    The discovery of safe and effective radiation countermeasures for long-duration spaceflight is challenging due to the complexity of the space radiation biology and high safety requirements.

  • Mega-High-Throughput Screening Platform for the Discovery of Biologically Relevant Sequence-Defined Non-Natural Polymers 

    We developed a novel technology for screening and sequencing libraries of synthetic molecules of up to a billion compounds in size.

  • Expanding the Metabolite Mimic Approach to Identify Hits for Mycobacterium Tuberculosis

  • A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents

    The feasibility of repurposing existing drugs to face novel threats is demonstrated and this represents the first effort to apply this approach to high containment bacteria and viruses.

  • Systematic Discovery of Synergistic Novel Antibiotic Combinations Targeting Multidrug-Resistant Acinetobacter Baumannii

  • Combining Cheminformatics Methods and Pathway Analysis to Identify Molecules with Whole-Cell Activity Against Mycobacterium Tuberculosis

    Our approach leverages the integration of intensive data mining and curation and computational approaches, including cheminformatics combined with bioinformatics, to suggest biological targets and their small molecule modulators.

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Career call to action image

Make your own mark.

Search jobs

Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Institute

Leadership

Press room

Media inquiries

Compliance

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter


日本支社
SRI International
  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2023 SRI International
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}